Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Income Taxes |
|
| Summary of domestic and foreign components of loss before taxes |
| | Year Ended December 31, | | | Year Ended December 31, | | | | 2025 | | | 2024 | | U.S. operations | | $ | 1,647,100 | | | $ | (4,390,100 | ) | Non-U.S. operations | | | (3,422,800 | ) | | | (3,633,500 | ) | Total loss before taxes | | $ | (1,775,700 | ) | | $ | (8,023,600 | ) |
| | | Year Ended December 31, 2025 | | | | | | | | | Amount | | | | Percent | | | | | | | | | | | U.S. federal statutory taxrate | | $ | (372,900 | ) | | $ | 21.00 | % | State income taxes, net of federal income taxeffect | | | 3,600 | | | | -0.20 | % | Foreign tax effects | | | | | | | | | Germany | | | | | | | | | Return to provision and other true ups | | | (2,025,500 | ) | | | 114.07 | % | Changes in valuation allowance | | | 2,025,475 | | | | -114.07 | % | Changes in valuation allowance | | | 1,167,225 | | | | -65.73 | % | Nontaxable or nondeductible items | Incentive Stock Options | | | 21,600 | | | | -1.22 | | Other | | | 3,700 | | | | -0.21 | | Return to Provision and other true ups | Depreciation | | | 6,800 | | | | -0.38 | % | Amortization | | | (1,247,200 | ) | | | 70.23 | % | Net Capitalized R&D Expenses | | | 466,900 | | | | -26.29 | % | Inventory Reserve | | | (11,300 | ) | | | 0.64 | % | Net Operating Loss | | | (36,700 | ) | | | 2.07 | % | Other | | | 2,900 | | | | -0.17 | % | Effective tax rate | | $ | 4,600 | | | | -0.26 | % |
|
| Income tax reconciliation |
| | 2024 | | | | Amount | | | | | | Federal tax expense | | $ | (1,353,500 | ) | State tax expense | | | - | | Research and Development Credits | | | (39,900 | ) | Incentive stock options | | | 38,700 | | Changes in valuation allowance | | | 537,100 | | Aquila Biolabs GmbH operating loss | | | (1,069,900 | ) | Return to provision and other true ups | | | 1,887,500 | | Provision for income taxes | | $ | - | |
|
| Deferred tax assets and liabilities |
| | As of December 31, | | | As of December 31, | | Deferred tax assets: | | 2025 | | | 2024 | | | | | | | | | Amortization of intangible assets, including goodwill | | $ | 1,016,800 | | | $ | - | | Research and development credits | | | 445,000 | | | | 466,300 | | Goodwill impairment | | | - | | | | 898,800 | | Net Capitalized R&D | | | 1,373,400 | | | | 1,509,700 | | Various accruals | | | - | | | | 134,000 | | Stock options expense | | | 1,625,200 | | | | 1,531,900 | | Net operating loss | | | 7,401,900 | | | | 5,422,900 | | Other | | | 1,175,300 | | | | 21,100 | | Subtotal | | $ | 13,037,600 | | | $ | 9,984,700 | | | | | | | | | | | Deferred tax liability: | | | | | | | | | Depreciation | | $ | (109,600 | ) | | $ | (46,800 | ) | Amortization of intangible assets, including goodwill | | | - | | | | (98,500 | ) | Subtotal | | | (109,600 | ) | | | (145,300 | ) | | | | | | | | | | Less valuation allowance | | | (12,928,000 | ) | | | (9,839,400 | ) | Net deferred tax assets | | $ | - | | | $ | - | |
|